Biomarkers of HIV-1-associated Neurocognitive Disorders: Challenges of Proteomic Approaches

Overview

Journal Biomark Med

Specialties Biochemistry
General Medicine

Date 2010 May 19

PMID 20477714

Citations 7

Authors

Pawel Ciborowski

Affiliations

Soon will be listed here.

Abstract

HIV-1 enters the brain shortly after infection, which may lead to neurological complications and in the most severe cases to encephalitis, dementia and death. The introduction of antiretroviral therapy reduced the incidence of the most severe conditions, nevertheless, approximately half of those infected with this virus will suffer to various degrees from HIV-1-associated neurocognitive disorders. Despite many years of research, there are no biomarkers that can objectively measure and, more importantly, predict the onset and the tempo of HIV-1-associated neurocognitive disorders. Here we review biomarker candidates of neurocognitive impairment due to HIV infection of the brain that have been proposed during the last two decades, and discuss perspectives and limitations of proteomic approaches in the search for new, more sensitive and specific biomarkers.

Citing Articles

Reduced neural specificity in middle-aged HIV+ women in the absence of behavioral deficits.

Liu C, Wang C, LeClair M, Young M, Jiang X Neuroimage Clin. 2015; 8:667-75.

PMID: 26288750 PMC: 4536469. DOI: 10.1016/j.nicl.2014.12.003.

Proteomics, biomarkers, and HIV-1: A current perspective.

Donnelly M, Ciborowski P Proteomics Clin Appl. 2015; 10(2):110-25.

PMID: 26033875 PMC: 4666820. DOI: 10.1002/prca.201500002.

Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count.

Adiga R, Ozdemir A, Carides A, Wasilewski M, Yen W, Chitturi P J Neurovirol. 2014; 20(4):371-9.

PMID: 24817145 PMC: 4104596. DOI: 10.1007/s13365-014-0252-8.

Comparison of 4-plex to 8-plex iTRAQ quantitative measurements of proteins in human plasma samples.

Pottiez G, Wiederin J, Fox H, Ciborowski P J Proteome Res. 2012; 11(7):3774-81.

PMID: 22594965 PMC: 3390908. DOI: 10.1021/pr300414z.

Plasma proteomic profiling in HIV-1 infected methamphetamine abusers.

Pottiez G, Jagadish T, Yu F, Letendre S, Ellis R, Duarte N PLoS One. 2012; 7(2):e31031.

PMID: 22359561 PMC: 3281056. DOI: 10.1371/journal.pone.0031031.

References

Pocernich C, Boyd-Kimball D, Poon H, Thongboonkerd V, Lynn B, Klein J . Proteomics analysis of human astrocytes expressing the HIV protein Tat. Brain Res Mol Brain Res. 2005; 133(2):307-16. DOI: 10.1016/j.molbrainres.2004.10.023. View

Rozek W, Horning J, Anderson J, Ciborowski P . Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment. Proteomics Clin Appl. 2010; 2(10-11):1498-507. PMC: 3406605. DOI: 10.1002/prca.200780114. View

Steiner J, Haughey N, Li W, Venkatesan A, Anderson C, Reid R . Oxidative stress and therapeutic approaches in HIV dementia. Antioxid Redox Signal. 2006; 8(11-12):2089-100. DOI: 10.1089/ars.2006.8.2089. View

Griffin D, Wesselingh S, McArthur J . Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol. 1994; 35(5):592-7. DOI: 10.1002/ana.410350513. View

Shi M, Caudle W, Zhang J . Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis. 2008; 35(2):157-64. PMC: 2939006. DOI: 10.1016/j.nbd.2008.09.004. View

Wang H, Qian W, Mottaz H, Clauss T, Anderson D, Moore R . Development and evaluation of a micro- and nanoscale proteomic sample preparation method. J Proteome Res. 2005; 4(6):2397-403. PMC: 1781925. DOI: 10.1021/pr050160f. View

Pena F, Ramirez J . Hypoxia-induced changes in neuronal network properties. Mol Neurobiol. 2005; 32(3):251-83. DOI: 10.1385/MN:32:3:251. View

Pratt R, Nichols S, McKinney N, Kwok S, Dankner W, Spector S . Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid of infected children. J Infect Dis. 1996; 174(2):288-93. DOI: 10.1093/infdis/174.2.288. View

Abbott A . Neuroscience: genomics on the brain. Nature. 2003; 426(6968):757. DOI: 10.1038/426757a. View

10.

Bowman G, Kaye J, Moore M, Waichunas D, Carlson N, Quinn J . Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007; 68(21):1809-14. PMC: 2668699. DOI: 10.1212/01.wnl.0000262031.18018.1a. View

11.

Irungu J, Go E, Zhang Y, Dalpathado D, Liao H, Haynes B . Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein. J Am Soc Mass Spectrom. 2008; 19(8):1209-20. PMC: 3706080. DOI: 10.1016/j.jasms.2008.05.010. View

12.

Reynolds A, Laurie C, Mosley R, Gendelman H . Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol. 2007; 82:297-325. DOI: 10.1016/S0074-7742(07)82016-2. View

13.

Zhou Y, Bhatia I, Cai Z, He Q, Cheung P, Chiu J . Proteomic analysis of neonatal mouse brain: evidence for hypoxia- and ischemia-induced dephosphorylation of collapsin response mediator proteins. J Proteome Res. 2008; 7(6):2507-15. DOI: 10.1021/pr800108k. View

14.

Ricardo-Dukelow M, Kadiu I, Rozek W, Schlautman J, Persidsky Y, Ciborowski P . HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J Neuroimmunol. 2007; 185(1-2):37-46. PMC: 2212599. DOI: 10.1016/j.jneuroim.2007.01.004. View

15.

Richman D, Fischl M, GRIECO M, Gottlieb M, Volberding P, Laskin O . The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):192-7. DOI: 10.1056/NEJM198707233170402. View

16.

Pillai S, Kosakovsky Pond S, Liu Y, Good B, Strain M, Ellis R . Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain. 2006; 129(Pt 7):1872-83. DOI: 10.1093/brain/awl136. View

17.

Boisse L, Gill M, Power C . HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin. 2008; 26(3):799-819, x. DOI: 10.1016/j.ncl.2008.04.002. View

18.

Letendre S, Lanier E, McCutchan J . Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. J Infect Dis. 1999; 180(2):310-9. DOI: 10.1086/314866. View

19.

Scher J, Pillinger M . The anti-inflammatory effects of prostaglandins. J Investig Med. 2009; 57(6):703-8. DOI: 10.2310/JIM.0b013e31819aaa76. View

20.

Saunders C, McCaffrey R, Zharkikh I, Kraft Z, Malenbaum S, Burke B . The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol. 2005; 79(14):9069-80. PMC: 1168758. DOI: 10.1128/JVI.79.14.9069-9080.2005. View